Recent progress in direct-acting antiviral agents for chronic hepatitis C
10.3969/j.issn.1001-5256.2014.06.004
- VernacularTitle:抗HCV小分子化合物的研究
- Author:
Minran LI
;
Xiaoyuan XU
- Publication Type:Journal Article
- Keywords:
hepatitis C virus;
enzyme inhibitors;
antiviral agent;
review
- From:
Journal of Clinical Hepatology
2014;30(6):493-495
- CountryChina
- Language:Chinese
-
Abstract:
The current standard treatment for hepatitis C virus (HCV)infection is a combination of pegylated interferon (PEG-IFN)and ribavirin.However,it remains incurable in some patients.In recent years,direct acting antiviral agents (DAAs)that target specific HCV enzymes in HCV life cycle have been developed rapidly.A combination of PEG-IFN,ribavirin,and DAAs can increase the sustained viro-logical response rate in patients with chronic hepatitis C (CHC).For patients who cannot use or tolerate interferon therapy,a combination of various DAAs has good efficacy.Therefore,DAAs bring new hope for the treatment of CHC.
